Abstract | BACKGROUND: PATIENTS AND METHODS: Thirty-one patients were treated with tamoxifen (20 mg p.o. daily), and fenretinide (400 mg p.o. daily with a 3-day drug holiday each month). Plasma TGF-beta testing was performed using isoform specific sandwich ELISA. RESULTS: Twenty four of the 31 patients were evaluable for an antitumor response including 14 estrogen receptor (ER) positive patients who had failed prior tamoxifen therapy, seven ER-negative patients, and three hormone therapy naive ER-positive patients. There were no objective antitumor responses; three patients had stable disease for 8, 8, and 24 months. Five patients (16%) discontinued therapy for toxicity (one for grade 3 skin rash and four for abnormal dark adaptation). There was a statistically significant decrease in total cholesterol (median change per patient of -13.5 mg/dl; p = 0.049, a 6.5% decrease), and an increase in HDL levels (median change per patient of +18 mg/dl, p = 0.0001, a 35% increase) with tamoxifen and fenretinide therapy. TGF-beta1 plasma levels were normal in 26 of 28 patients, and no changes in these levels post-treatment were demonstrated. CONCLUSIONS:
|
Authors | J Zujewski, L Pai, L Wakefield, R Giusti, F A Dorr, C Flanders, R Caruso, M Kaiser, L Goodman, M Merino, M Gossard, M A Noone, A Denicoff, D Venzon, K H Cowan, J A O'Shaughnessy |
Journal | Breast cancer research and treatment
(Breast Cancer Res Treat)
Vol. 57
Issue 3
Pg. 277-83
(Oct 1999)
ISSN: 0167-6806 [Print] Netherlands |
PMID | 10617304
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Lipids
- Transforming Growth Factor beta
- Tamoxifen
- Fenretinide
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Disease Progression
- Female
- Fenretinide
(administration & dosage)
- Humans
- Lipids
(blood)
- Middle Aged
- Pilot Projects
- Tamoxifen
(administration & dosage)
- Transforming Growth Factor beta
(analysis)
- Treatment Outcome
|